RuHan Genomics Completes Tens of Millions RMB Angel Funding to Accelerate Development of Solid-State Nanopore Sequencing and Biomolecular Detection Technologies
Recently, Shenzhen Ruhan Gene Technology Co., Ltd. (hereinafter referred to as “Ruhan Gene”) completedTens of Millions of RMB in Angel Financing Led by Lihe Sci-Tech Venture Capital, the proceeds from the financing will be used for technology R&D, equipment procurement, and team building. Previously, Ruhan Gene secured seed funding from Hengbang Capital in December 2019.
Ruhan Gene FusionBioengineering and Genomics, Semiconductor Process Technology, AI Big Data Analytics Technology, Micro- and Nanotechnologysuch as the latest technologies, and develop products with independent intellectual property rightsDetection of Biological Macromolecules, Including Fourth-Generation Gene Sequencing and Nanopore Viral DetectionRelated equipment.
Ruhan Gene’s environmental biosafety monitoring system has achieved commercial deployment, enabling automated detection of over 40 pathogenic microorganisms in ambient air, including SARS-CoV-2. The system facilitates unattended, on-site viral analysis and testing with a fully automated and intelligent workflow. It supports routine epidemic prevention and control measures and is widely applied in relatively enclosed spaces such as customs ports, airports, subway stations, schools, and hospitals, representing substantial market potential.
Regarding the securing of this round of financing,Mo Hui, Founder of Ruhan GeneResponse: We extend our sincere gratitude to Lihe Sci-Tech Venture Capital for their recognition of our team. Moving forward, Ruhan Genomics will remain committed to achieving “independent, secure, and controllable” core technologies. We will deliver high-quality products and services in the field of biomolecular detection, create value for our customers, and drive industry development. By promoting the widespread application of gene technology in areas such as healthcare and life safety, we aim to contribute to the “Healthy China” initiative.
Regarding the investment in Ruhan Genomics,Hu Yang, Partner at Lihe Sci-Tech Venture CapitalIt is acknowledged that the automated genetic testing industry is one of the most promising sectors both currently and in the future. Ruhan Genetics has mastered core technologies, including solid-state nanopore devices, microfluidic chips, weak signal measurement, and AI-based algorithms for virus and base calling, thereby addressing key pain points such as the variability and short lifespan of biological nanopores, which has earned widespread recognition within the industry. The nanopore gene sequencer project and the airborne environmental biosafety monitoring project align with industrial development, market demand, and policy trends, demonstrating urgent market needs and substantial growth potential.
Lighe Kechuang Venture Capital is a specialized management institution under the Shenzhen Tsinghua University Research Institute, dedicated to fund management and equity investment. The team comprises seasoned professionals from both domestic and international markets with expertise in fund management, equity investment, and capital operations. With assets under management reaching billions of yuan, the firm has established a successful, innovation-driven model that combines venture capital with incubation and cultivation, primarily focusing on early- and mid-stage high-tech enterprises, and has delivered outstanding investment returns.
Historically, the company and its team have invested in and incubated over 400 technology enterprises in fields such as new energy, electronic information, new materials, biopharmaceuticals, energy conservation and environmental protection, and opto-mechanical-electrical integration through direct investments and fund investments. Among these, more than 70 have achieved successful exits, and nearly 30 companies backed by direct and fund investments are currently listed on China’s A-share market.